

Special Issue

COVID Vaccines: Design, Development, and Immune Response Studies: 2nd Edition

Message from the Guest Editors

COVID-19 vaccines represented an unprecedented effort to contain the pandemic. Developed in record time, they have saved millions of lives over the past few years. Nevertheless, there is still room for improvement on different fronts, ranging from the elicitation of mucosal immunity and the prevention of transmission to their ability to elicit greater immune responses in immunocompromised patients. While it is currently not clear whether yearly boosts will continue to be required, multivalent vaccines based on updated versions of the Spike protein are under development, as well as vaccines based on SARS-CoV-2 antigens other than Spike and combination vaccines with flu and pneumococcus. In this Special Issue, we welcome original research and systematic reviews on vaccine design, immune responses, and different boosting protocols.

Guest Editors

Dr. Fabrizio Maggi

Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy

Dr. Licia Bordi

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Via Portuense 292, 00149 Rome, Italy

Deadline for manuscript submissions

30 November 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/207570

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).